Binding Sites of Cytoplasmic Effectors TRAF1, 2, and 3 on CD30 and Other Members of the TNF Receptor Superfamily

doi:10.1006/bbrc.1997.6509

Biochemical and Biophysical Research Communications

Volume 233, Issue 3, 28 April 1997, Pages 592-600

https://doi.org/10.1006/bbrc.1997.6509 Get rights and content

Abstract

CD30 is present on the surfaces of malignant cells from patients with Hodgkin's lymphoma, anaplastic large cell lymphoma, and other lymphomas. The yeast two hybrid genetic screen method was used to identify molecular effectors which mediate CD30 signalling events. Clones corresponding to genes coding for TRAF1, TRAF2, and TRAF3 molecules, postulated to be involved in signalling via the TNF and CD40 receptors, were isolated. In this report, we show that the CD30 intracellular tail contains two motifs that bind TRAFs. The more amino terminal motif,⁵⁵⁸PHYPEQET⁵⁶⁵, binds TRAF2 and 3, while the more carboxyl terminal motif,⁵⁷⁶MLSVEEEG⁵⁸³, binds TRAF1 and 2. We show that these amino acid motifs are conserved in TNFRp75 and CD40 and that sequences in these receptors homologous to TRAF-binding sequences found in CD30 can selectively bind the TRAFs in a predictable manner.

References (45)

B. Falini et al.
Blood
(1995)
H.J. Gruss et al.
Blood
(1995)
C.A. Smith et al.
Cell
(1994)
K. Pfeffer et al.
Cell
(1993)
N. Itoh et al.
Cell
(1991)
H.J. Gruss et al.
Blood
(1994)
R. Amakawa et al.
Cell
(1996)
M. Rothe et al.
Cell
(1994)
T. Sato et al.
FEBS Lett.
(1995)
H.M. Hu et al.
J. Biol. Chem.
(1994)

Cited by (90)

Roles for TNF-receptor associated factor 3 (TRAF3) in lymphocyte functions
2014, Cytokine and Growth Factor Reviews
TRAF3 is an adapter protein that serves and regulates the functions of several types of receptors, located both inside the cell and at the plasma membrane. These include members of the TNF receptor superfamily (TNFR-SF), toll-like receptors (TLR), and cytokine receptors. It has become increasingly evident that the roles and functions of TRAF3 are highly context-dependent. TRAF3 can serve distinct roles for different receptors in the same cell, and also has highly cell-type-dependent functions. This review focuses upon the current state of knowledge regarding how TRAF3 regulates the biology and effector functions of B and T lymphocytes, two major cell types of the adaptive immune response in which TRAF3 has markedly distinct roles.
NF-κB signal triggering and termination by tumor necrosis factor receptor 2
2011, Journal of Biological Chemistry
Citation Excerpt :
As for the interaction of TRAF2 and TNFR2, by using sequential truncations of the receptor cytoplasmic tail (amino acids 266–439), a sequence comprising amino acids 384 to 423 was proposed to be responsible of TRAF2 recruitment (14). Further analysis of this sequence limited the TRAF2 binding motif to amino acids 402-SKEE-405 (15, 16). More recently, another TRAF2 binding site with a suggested negative regulatory role has been identified on the murine TNFR2 (17).
Tumor necrosis factor receptor 2 (TNFR2) activates transcription factor κB (NF-κB) and c-Jun N-terminal kinase (JNK). The mechanisms mediating these activations are dependent on the recruitment of TNF receptor-associated factor 2 (TRAF2) to the intracellular region of the receptor. TNFR2 also induces TRAF2 degradation. We show that in addition to the well characterized TRAF2 binding motif 402-SKEE-405, the human receptor contains another sequence located at the C-terminal end (amino acids 425–439), which also recruits TRAF2 and activates NF-κB. In addition to that, human TNFR2 contains a conserved region (amino acids 338–379) which is responsible for TRAF2 degradation and therefore of terminating NF-κB signaling. TRAF2 degradation and the lack of NF-κB activation when both TNFR1 and TNFR2 are co-expressed results in an enhanced ability of TNFR1 to induce cell death, showing that the cross-talk between both receptors is of a great biological relevance. Induction of TRAF2 degradation appears to be independent of TRAF2 binding to the receptor. Amino acids 343-TGSSDSS-349 are essential for inducing TRAF2 degradation because deletion mutants of this region or point mutations at serine residues 345 and 346 or 348 and 349 obliterate the ability of TNFR2 to induce TRAF2 degradation.
Ligand-induced internalization of TNF receptor 2 mediated by a di-leucin motif is dispensable for activation of the NFκB pathway
2011, Cellular Signalling
Endocytosis is an important mechanism to regulate tumor necrosis factor (TNF) signaling. In contrast to TNF receptor 1 (TNFR1; CD120a), the relevance of receptor internalization for signaling as well as the fate and route of internalized TNF receptor 2 (TNFR2; CD120b) is poorly understood. To analyze the dynamics of TNFR2 signaling and turnover at the plasma membrane we established a human TNFR2 expressing mouse embryonic fibroblast cell line in a TNFR1^−/−/TNFR2^−/− background. TNF stimulation resulted in a decrease of constitutive TNFR2 ectodomain shedding. We hypothesized that reduced ectodomain release is a result of TNF/TNFR2 complex internalization. Indeed, we could demonstrate that TNFR2 was internalized together with its ligand and cytoplasmic binding partners. Upon endocytosis the TNFR2 signaling complex colocalized with late endosome/lysosome marker Rab7 and entered the lysosomal degradation pathway. Furthermore, we identified a di-leucin motif in the cytoplasmic part of TNFR2 suggesting clathrin-dependent internalization of TNFR2. Internalization defective TNFR2 mutants are capable to signal, i.e. activate NFκB, demonstrating that the di-leucin motif dependent internalization is dispensable for this response. We therefore propose that receptor internalization primarily serves as a negative feed-back to limit TNF responses via TNFR2.
TRAF1 is involved in the classical NF-κB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells
2009, Molecular Immunology
TNFR-associated factors (TRAFs) participate in diverse biological processes, such as adaptive and innate immunity, stress response, and bone metabolism. We report that all TRAFs except TRAF3 are expressed at mRNA and protein levels in B cell-derived Hodgkin's lymphoma cell lines (L428 and KM-H2). Both the classical (p50–RelA) and the alternative NF-κB activity (p52–RelB) are sustained in L428 and KM-H2 cells. A successful depletion of TRAF1 protein expression by means of RNA interference abrogates the anti-apoptosis activity in L428 cells. The TRAF1-deficiency reduces the classical NF-κB activity but not the alternative activity. The expression of the NF-κB targeting genes, such as ICAM-1, c-Flip, and Cyclin D1, is suppressed in the TRAF1-depleted cells. On the other hand, CD30 signaling upregulates the TRAF1 expression while reducing the expression of TRAF2 and TRAF5. Importantly, the CD30-induced alternative NF-κB activation is inhibited by the depletion of the TRAF1 expression. We also demonstrate that the phosphorylation of the extracellular signal-regulated kinase (ERK) upon CD30 stimulation in Hodgkin's lymphoma cells is independent of TRAF1 expression. Our data shed new light on the function of TRAF1 in B cell-derived lymphoma cells. We conclude that TRAF1 is an important molecule mediating both the CD30 signaling-dependent and independent NF-κB activation, which prevents the lymphoma cells from spontaneous and induced apoptosis.
Roles of TRAF molecules in B lymphocyte function
2008, Cytokine and Growth Factor Reviews
Tumor necrosis factor receptor associated factors (TRAFs) play a variety of interesting and important roles in the regulation of B lymphocyte function. They act both as cytoplasmic regulatory molecules, and as signal transducers for receptors involved in both innate and adaptive humoral immune responses. In this brief review, we highlight the current state of knowledge of the diverse roles of TRAF molecules in the functions of B lymphocytes.
The in vivo function of a noncanonical TRAF2-binding domain in the C-terminus of CD40 in driving B-cell growth and differentiation
2007, Blood
Citation Excerpt :
Previously, to investigate the molecular mechanisms of CD40 signaling and how downstream signaling events control CD40-mediated immune responses, several approaches both in vitro and in vivo have been undertaken. In those studies, different TRAF-binding sites within the CD40 cytoplasmic domain have been identified.12–17 Mutagenesis of those defined TRAF-binding sites elucidated specific CD40-TRAF associations in regulating downstream signal transduction as well as controlling defined aspects of humoral immunity.18,19
The recruitment of tumor necrosis factor receptor–associated factors (TRAFs) 1, 2, 3, 5, and 6 to the CD40 cytoplasmic tail upon CD40 trimerization results in downstream signaling events that ultimately lead to CD40-dependent, thymus-dependent (TD) humoral immune responses. Previously, we have shown signaling through the C-terminal tail of CD40 in the absence of canonical TRAF-binding sites is capable of signaling through an alternative TRAF2-binding site. Here, we demonstrate that B cells from mice harboring CD40 with only the C-terminal tail can activate both canonical and noncanonical NFκB signaling pathways. Moreover, while lacking germinal center formation, several hallmarks of humoral immune responses including clonal B-cell activation/expansion, antibody isotype switching, and affinity maturation remain normal. This study demonstrates a new functional domain in CD40 that controls critical aspects of B-cell immunity in an in vivo setting.

View all citing articles on Scopus

View full text

Regular ArticleBinding Sites of Cytoplasmic Effectors TRAF1, 2, and 3 on CD30 and Other Members of the TNF Receptor Superfamily

Abstract

Blood

Blood

Cell

Cell

Cell

Blood

Cell

Cell

FEBS Lett.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

Cell

J. Biol. Chem.

J. Biol. Chem.

Adv. Virus Res.

Cell

Cell

Cell

Nature

J. Immunol.

Regular Article
Binding Sites of Cytoplasmic Effectors TRAF1, 2, and 3 on CD30 and Other Members of the TNF Receptor Superfamily